A detailed history of Oxbow Advisors, LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Oxbow Advisors, LLC holds 7,359 shares of ABBV stock, worth $1.48 Million. This represents 0.17% of its overall portfolio holdings.

Number of Shares
7,359
Previous 7,359 -0.0%
Holding current value
$1.48 Million
Previous $1.34 Million 5.82%
% of portfolio
0.17%
Previous 0.19%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 06, 2024

BUY
$159.82 - $182.1 $46,987 - $53,537
294 Added 4.16%
7,359 $1.34 Million
Q4 2023

Feb 08, 2024

SELL
$137.6 - $154.97 $71,139 - $80,119
-517 Reduced 6.82%
7,065 $1.09 Million
Q3 2023

Nov 14, 2023

BUY
$133.59 - $154.65 $161,911 - $187,435
1,212 Added 19.03%
7,582 $1.13 Million
Q2 2023

Aug 04, 2023

SELL
$132.51 - $164.9 $11,925 - $14,841
-90 Reduced 1.39%
6,370 $858,000
Q1 2023

Apr 25, 2023

SELL
$144.61 - $166.54 $7,375 - $8,493
-51 Reduced 0.78%
6,460 $1.03 Million
Q4 2022

Feb 01, 2023

SELL
$138.31 - $165.87 $14,384 - $17,250
-104 Reduced 1.57%
6,511 $1.05 Million
Q3 2022

Nov 03, 2022

BUY
$134.21 - $153.93 $28,586 - $32,787
213 Added 3.33%
6,615 $888,000
Q2 2022

Aug 10, 2022

BUY
$137.62 - $174.96 $24,909 - $31,667
181 Added 2.91%
6,402 $981,000
Q1 2022

May 09, 2022

SELL
$131.98 - $163.75 $353,574 - $438,686
-2,679 Reduced 30.1%
6,221 $1.01 Million
Q4 2021

Feb 09, 2022

SELL
$107.43 - $135.93 $7,520 - $9,515
-70 Reduced 0.78%
8,900 $1.21 Million
Q3 2021

Nov 10, 2021

SELL
$106.4 - $120.78 $1,915 - $2,174
-18 Reduced 0.2%
8,970 $968,000
Q2 2021

Aug 04, 2021

BUY
$105.21 - $117.21 $1,893 - $2,109
18 Added 0.2%
8,988 $1.01 Million
Q1 2021

May 11, 2021

SELL
$102.3 - $112.62 $221,479 - $243,822
-2,165 Reduced 19.44%
8,970 $971,000
Q4 2020

Feb 02, 2021

BUY
$80.49 - $108.67 $30,183 - $40,751
375 Added 3.49%
11,135 $1.19 Million
Q3 2020

Nov 06, 2020

BUY
$85.91 - $100.83 $102,232 - $119,987
1,190 Added 12.43%
10,760 $942,000
Q2 2020

Aug 12, 2020

SELL
$73.37 - $98.18 $93,693 - $125,375
-1,277 Reduced 11.77%
9,570 $940,000
Q1 2020

May 06, 2020

SELL
$64.5 - $97.79 $2,902 - $4,400
-45 Reduced 0.41%
10,847 $826,000
Q4 2019

Feb 06, 2020

SELL
$72.13 - $90.25 $153,636 - $192,232
-2,130 Reduced 16.36%
10,892 $964,000
Q3 2019

Oct 31, 2019

SELL
$62.98 - $75.72 $6.13 Million - $7.37 Million
-97,337 Reduced 88.2%
13,022 $986,000
Q2 2019

Aug 07, 2019

BUY
$65.7 - $83.98 $1.96 Million - $2.5 Million
29,771 Added 36.94%
110,359 $8.03 Million
Q1 2019

May 01, 2019

SELL
$77.14 - $90.79 $211,517 - $248,946
-2,742 Reduced 3.29%
80,588 $6.5 Million
Q4 2018

Feb 12, 2019

BUY
$77.85 - $96.01 $1.09 Million - $1.34 Million
14,004 Added 20.2%
83,330 $7.68 Million
Q3 2018

Nov 06, 2018

BUY
$88.91 - $98.84 $274,731 - $305,415
3,090 Added 4.67%
69,326 $6.56 Million
Q2 2018

Aug 09, 2018

SELL
$89.78 - $106.23 $215,651 - $255,164
-2,402 Reduced 3.5%
66,236 $6.14 Million
Q1 2018

Apr 30, 2018

SELL
$92.01 - $123.21 $959,940 - $1.29 Million
-10,433 Reduced 13.19%
68,638 $6.5 Million
Q4 2017

Jan 30, 2018

SELL
$89.56 - $98.21 $156,013 - $171,081
-1,742 Reduced 2.16%
79,071 $7.65 Million
Q3 2017

Oct 23, 2017

BUY
$69.85 - $89.22 $5.64 Million - $7.21 Million
80,813
80,813 $7.18 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $356B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Oxbow Advisors, LLC Portfolio

Follow Oxbow Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Oxbow Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Oxbow Advisors, LLC with notifications on news.